STX-0119|cas:851095-32-4|西域试剂

STX-0119,99.21%

产品编号：Bellancom-103692| CAS NO：851095-32-4| 分子式：C₂₂H₁₄N₄O₃| 分子量：382.37

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-103692	￥1200.00	杭州北京（现货）
Bellancom-103692	￥1900.00	杭州北京（现货）
Bellancom-103692	￥3800.00	杭州北京（现货）
Bellancom-103692	￥6200.00	杭州北京（现货）
Bellancom-103692	￥9800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

STX-0119

产品介绍

STX-0119 是一种选择性的、具有口服活性的 STAT3 二聚抑制剂。STX-0119 抑制 STAT3 转录，IC₅₀ 为 74 μM。

生物活性

STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM.

体外研究

STX-0119 (10-50 μM; 24 h) inhibits STAT3 dimerization through a direct interaction with the STAT3 protein and not via the modulation of upstream regulators such as JAK in HEK293 and MDA-MB-468 cells.
STX-0119 (10-50 μM; 24 h) reduces the expression of STAT3 target proteins.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	MDA-MB-468 cells
Concentration:	10, 20 and 50 μM
Incubation Time:	24 h
Result:	Reduced the expression of STAT3 target proteins, namely, c-myc, cyclin D1, and survivin, in a concentration-dependent manner. Did not suppress the expression of those STAT3-regulated oncoproteins.

体内研究
(In Vivo)

STX-0119 (160 mg/kg; oral gavage; daily for 4 days) inhibits SCC-3 tumor growth in mice.
The plasma concentration of STX-0119 (160 mg/kg; oral gavage) is maintained at >100 μg/mL (>260 μM), even at 8 h after administration.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/cA-ν/ν nude mice, SCC-3 lymphoma xenograft model
Dosage:	160 mg/kg
Administration:	Oral gavage, daily for 4 days
Result:	Suppressed the growth of SCC-3 cells significantly on the fourth day.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/cA-ν/ν nude mice, SCC-3 lymphoma xenograft model
Dosage:	160 mg/kg
Administration:	Oral gavage, daily for 4 days
Result:	Suppressed the growth of SCC-3 cells significantly on the fourth day.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/cA-ν/ν nude mice, SCC-3 lymphoma xenograft model
Dosage:	160 mg/kg
Administration:	Oral gavage, daily for 4 days
Result:	Suppressed the growth of SCC-3 cells significantly on the fourth day.